BioWorld - Tuesday, June 2, 2020

Transforming drug, med-tech R&D with AI

AI_landscape.png

 

 

 

 

 

 

 

 

Published August 2019

Deals analysis

Transforming R&D and health care with artificial intelligence

Biopharmas move into deep waters of massive data, high R&D potential

AI propels med tech into new partnerships, new possibilities

Global regulatory impacts

U.S. AI med-tech regs in development ‘not for the faint of heart’

FDA looks to AI to streamline drug development and approval process

American AI Initiative

China on the cusp of regulating AI-based devices

Japan to develop assessment system to speed up AI development

Australia: No plans to regulate AI, machine learning via separate pathway

South Korea’s insurance, personal information law slows use of AI devices

India lags in regulating AI as development proceeds

The scientific black box – changing skillsets – intellectual property

AI’s superpowers lie in questions, not answers

Across the great (skills) divide

Supreme Court’s Alice decision leaves drug, device firms in AI wonderland

Research hospitals push AI beyond pattern recognition

Follow the money

What if artificial intelligence invents something?

Digital health financings sees continued momentum

VC meeting at the crossroads of biopharma R&D, computation

Clinical trials integration

AI starting to improve efficiency in med-tech clinical trials

AI in the clinic opens new vistas for biopharma investigators

AI in Asia-Pacific

Putting the AI in ASEAN

AI is expected to drive health care effectiveness, increase jobs in Australia

Challenges, opportunities and ethics

Ethical issues trailing AI are writ large in health care

At the crossroads of people and technology